Therapeutic Antagonism between Anticholinergic Antiparkinsonism Agents and Neuroleptics in Schizophrenia
- 1 January 1979
- journal article
- research article
- Published by S. Karger AG in Neuropsychobiology
- Vol. 5 (2) , 74-86
- https://doi.org/10.1159/000117667
Abstract
Systematic data from three studies suggest that anticholinergic antiparkinsonism agents, when added to ongoing neuroleptic treatment in schizophrenics, have the effect of arresting or reversing therapeutic changes, and when given alone to untreated patients, tend to further worsen their psychosis. The countertherapeutic effects of anticholinergic drugs are reflected particularly in parameters which represent features of schizophrenic psychosis most consistently responsive to neuroleptics. It is proposed that these anticholinergic effects are central in origin and point to the involvement of cholinergic mechanisms in the expression of schizophrenic psychosis and its improvement with neuroleptic medication.Keywords
This publication has 7 references indexed in Scilit:
- Nosological and Prognostic Distinctions in Schizophrenia: Pharmacological Validation in Terms of Therapeutic Antagonism between Anticholinergic Anti-Parkinsonism Drugs and NeurolepticsNeuropsychobiology, 1978
- INFLUENCE OF ANTIPARKINSONIAN DRUGS ON PLASMA-LEVEL OF NEUROLEPTICS1977
- Reversal by a central antiacetylcholine drug of pimozideinduced inhibition of mouse-jumping in amphetamine-dopa treated miceJournal of Pharmacy and Pharmacology, 1975
- Study on the excitation induced by amphetamine, cocaine and ?-methyltryptaminePsychopharmacology, 1967
- Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patientsPsychopharmacology, 1966
- On certain psychopharmacological and physiological differences between schizophrenic and normal personsPsychopharmacology, 1965
- THE INHIBITION OF THE CONDITIONED RESPONSE AND THE COUNTERACTION OF SCHIZOPHRENIA BY MUSCARINIC STIMULATION OF THE BRAINAnnals of the New York Academy of Sciences, 1957